Prescient’s (ASX:PTX) PTX-100 demonstrates encouraging clinical activity in T cell lymphomas
Clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX), has provided an upbeat update regarding the encouraging clinical...
Clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX), has provided an upbeat update regarding the encouraging clinical...
Prescient Therapeutics Ltd (ASX:PTX) CEO and managing director Steven Yatomi-Clarke chats with Andrew Scott from Proactive about the...
Prescient’s PTX-100 Phase 1b study shows encouraging responses on a patient population that is notoriously...
Prescient Therapeutics Ltd (ASX:PTX) continues to demonstrate a favourable safety profile with its PTX-100 Phase 1b expansion...
A study by Prescient Therapeutics (ASX: PTX) into the effects of lead drug PTX-100 on relapsed and...
“It is very exciting to see PTX-100 show clinical activity in a patient population that...
A study by Prescient Therapeutics (ASX: PTX) into the effects of lead drug PTX-100 on relapsed and...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke presented at the...
Prescient Therapeutics Ltd (ASX:PTX) has brought in another A$2.5 million in a top-up placement to cater...
“It is a significant achievement to exceed our target amidst challenging market conditions,” said managing...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.